Cargando…

Targeting immune checkpoints in hematological malignancies

Immune checkpoint blockade (ICB) therapies such as anti-programmed death 1 (PD-1) and anti-CTLA-4 (cytotoxic T lymphocyte-associated protein 4) have dramatically transformed treatment in solid tumor oncology. While immunotherapeutic approaches such as stem cell transplantation and anti-cancer monocl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Salik, Basit, Smyth, Mark J., Nakamura, Kyohei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7425174/ https://www.ncbi.nlm.nih.gov/pubmed/32787882 http://dx.doi.org/10.1186/s13045-020-00947-6

Ejemplares similares

Checkpoint inhibitors in hematological malignancies
por: Ok, Chi Young, et al.
Publicado: (2017)

Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies
por: Wang, Hao, et al.
Publicado: (2019)

Toxicity of Immune-Checkpoint Inhibitors in Hematological Malignancies
por: Hradska, Katarina, et al.
Publicado: (2021)

Checkpoint inhibition in hematologic malignancies
por: Tsumura, Aaron, et al.
Publicado: (2023)

Targeting immune checkpoints in malignant glioma
por: Zhang, Xuhao, et al.
Publicado: (2016)

Hematologic malignancies following immune checkpoint inhibition for solid tumors
por: van Eijs, Mick J. M., et al.
Publicado: (2022)

Hematologic Complications of Immune Checkpoint Inhibitors
por: Davis, Elizabeth J., et al.
Publicado: (2019)

Management of Hematologic Adverse Events Associated With Immune Checkpoint Inhibitors
por: Rogers, Barbara Barnes, et al.
Publicado: (2021)

Hematologic complications of immune checkpoint inhibitors
por: Kroll, Michael H., et al.
Publicado: (2022)

Invasive Fungal Diseases in Children with Hematological Malignancies Treated with Therapies That Target Cell Surface Antigens: Monoclonal Antibodies, Immune Checkpoint Inhibitors and CAR T-Cell Therapies
por: Kyriakidis, Ioannis, et al.
Publicado: (2021)

Hematological and Extra-Hematological Autoimmune Complications after Checkpoint Inhibitors
por: Fattizzo, Bruno, et al.
Publicado: (2022)

Immune Therapies for Hematologic Malignancies
por: Olnes, Matthew J.
Publicado: (2021)

Could Immune Checkpoint Disorders and EBV Reactivation Be Connected in the Development of Hematological Malignancies in Immunodeficient Patients?
por: Mertowska, Paulina, et al.
Publicado: (2023)

Targeting DNA Repair Pathways in Hematological Malignancies
por: Alhmoud, Jehad F., et al.
Publicado: (2020)

BCL-2 as therapeutic target for hematological malignancies
por: Perini, Guilherme Fleury, et al.
Publicado: (2018)

Targeting the integrated stress response in hematologic malignancies
por: Nwosu, Gus O., et al.
Publicado: (2022)

Role of Immune Checkpoint Inhibitors in Gastrointestinal Malignancies
por: Mazloom, Anita, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors for Gastrointestinal Malignancies: An Update
por: DeCarli, Kathryn, et al.
Publicado: (2022)

Targeting nuclear import and export in hematological malignancies
por: Nachmias, Boaz, et al.
Publicado: (2020)

Emerging Metabolic Targets in the Therapy of Hematological Malignancies
por: Leni, Zaira, et al.
Publicado: (2013)

Immune Microenvironment in Hematologic Malignancies
por: Arandi, Nargess, et al.
Publicado: (2023)

Targeting p53 by small molecules in hematological malignancies
por: Saha, Manujendra N, et al.
Publicado: (2013)

Targeting hedgehog signaling in myelofibrosis and other hematologic malignancies
por: Tibes, Raoul, et al.
Publicado: (2014)

Invasive Fungal Infections and Targeted Therapies in Hematological Malignancies
por: Little, Jessica S., et al.
Publicado: (2021)

Impact of Histone Modifications and Their Therapeutic Targeting in Hematological Malignancies
por: Markouli, Mariam, et al.
Publicado: (2022)

Protein Arginine Methyltransferases as Therapeutic Targets in Hematological Malignancies
por: Sauter, Camille, et al.
Publicado: (2022)

Targeting CD22 for B-cell hematologic malignancies
por: Xu, Jia, et al.
Publicado: (2023)

Checkpoint Inhibitors and Engineered Cells: New Weapons for Natural Killer Cell Arsenal Against Hematological Malignancies
por: Giuliani, Massimo, et al.
Publicado: (2020)

Expression of Immune Checkpoints in Malignant Tumors: Therapy Targets and Biomarkers for the Gastric Cancer Prognosis
por: Mansorunov, Danzan, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors to Treat Malignant Lymphomas
por: Witkowska, Magdalena, et al.
Publicado: (2018)

Facing challenges with hope: universal immune cells for hematologic malignancies
por: Wang, Yuqing, et al.
Publicado: (2023)

Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies
por: Tapia-Galisteo, Antonio, et al.
Publicado: (2023)

T lymphocyte-targeted immune checkpoint modulation in glioma
por: Kelly, William James, et al.
Publicado: (2020)

Deubiquitinases in hematological malignancies
por: Lei, Hu, et al.
Publicado: (2021)

Autophagy in Hematological Malignancies
por: García Ruiz, Olga, et al.
Publicado: (2022)

Therapeutic Targeting of the Macrophage Immune Checkpoint CD47 in Myeloid Malignancies
por: Chao, Mark P., et al.
Publicado: (2020)

Adverse Hematological Effects of COVID-19 Vaccination and Pathomechanisms of Low Acquired Immunity in Patients with Hematological Malignancies
por: Yazdani, Armand N., et al.
Publicado: (2023)

Target Therapy in Hematological Malignances: New Monoclonal Antibodies
por: Podhorecka, Monika, et al.
Publicado: (2014)

Therapeutic Targeting of Notch Signaling Pathway in Hematological Malignancies
por: Sorrentino, Claudia, et al.
Publicado: (2019)

Immune-based Therapies for Hematological Malignancies: An Update by the EHA SWG on Immunotherapy of Hematological Malignancies
por: Einsele, Hermann, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ktn6ba6e7bhpcuqhodf0iv74lk